CAS 1189959-13-4|Lidocaine-d10 hydrochloride
Introduction：Basic information about CAS 1189959-13-4|Lidocaine-d10 hydrochloride, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Lidocaine-d10 hydrochloride | ||
|---|---|---|---|
| CAS Number | 1189959-13-4 | Molecular Weight | 278.84800 |
| Density | / | Boiling Point | / |
| Molecular Formula | C14H15ClD8N2O | Melting Point | / |
| MSDS | / | Flash Point | / |
Names
| Name | Lidocaine-d10 hydrochloride |
|---|---|
| Synonym | More Synonyms |
Lidocaine-d10 hydrochloride BiologicalActivity
| Description | Lidocaine-d10 (Lignocaine-d10) hydrochloride is the deuterium labeled Lidocaine hydrochloride. Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative commonly used to anesthetize. hydrochloride is a a drug to treat ventricular arrhythmia and an effective tumor-inhibitor[2]. |
|---|---|
| Related Catalog | Signaling Pathways >>Membrane Transporter/Ion Channel >>Sodium ChannelSignaling Pathways >>Apoptosis >>ApoptosisResearch Areas >>CancerSignaling Pathways >>MAPK/ERK Pathway >>MEKResearch Areas >>Cardiovascular DiseaseSignaling Pathways >>MAPK/ERK Pathway >>ERKSignaling Pathways >>Stem Cell/Wnt >>ERK |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
| References | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582(Pt 1):11. [3]. Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19(1):233. [4]. Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113(1):31-6. |
Chemical & Physical Properties
| Molecular Formula | C14H15ClD8N2O |
|---|---|
| Molecular Weight | 278.84800 |
| Exact Mass | 278.20000 |
| PSA | 35.83000 |
| LogP | 4.03520 |
| InChIKey | IYBQHJMYDGVZRY-OCNRKMBFSA-N |
| SMILES | CCN(CC)CC(=O)Nc1c(C)cccc1C.Cl |
Synonyms
| 2-[bis(pentadeuterioethyl)amino]-N-(2,6-dimethylphenyl)acetamide hydrochloride |
| 2-(bis(perdeuterioethyl)amino)-N-(2,6-dimethylphenyl)acetamide hydrochloride |
